Population pharmacokinetics of exendin‐(9‐39) and clinical dose selection in patients with congenital hyperinsulinism

AIMS: Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycaemia in infants and children. Exendin‐(9‐39), an inverse glucagon‐like peptide 1 (GLP‐1) agonist, is a novel therapeutic agent for HI that has demonstrated glucose‐raising effect. We report the first population pha...

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Ng, Chee M., Tang, Fei, Seeholzer, Steven H., Zou, Yixuan, De León, Diva D.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2017
Subjects:
Methods in Clinical Pharmacology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809353/
https://ncbi.nlm.nih.gov/pubmed/29077992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13463
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items